The effect of N- Acetyl cysteine on symptoms in patients with chronic schizophrenia
Phase 2
- Conditions
- schizophrenia.Schizophrenia
- Registration Number
- IRCT201106031556N21
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Inclusion Criteria: 1-Age between 18-50, 2-Diagnosis of Schizophrenia based on DSM IV 3-chronic Schizophrenia, 4-Minimum Score of 60 on Positive and Negative Scale
exclusion criteria:1- Substance dependence,2- IQ <70,3-any other mental disorder on axis I, 4-Any serious medical or neurological problem ,5- receiving oral antipsychotic medications during the last week or receiving any depot antipsychotic medication during the last month,6- receiving ECT during the last 14 days 7-sensitivity to N-acetyl cysteine
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of schizophrenia. Timepoint: Baseline and weeks 2-4-6-8 after beginig of treatment. Method of measurement: Positive and Negative Syndrome Scale (PANSS).
- Secondary Outcome Measures
Name Time Method